These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 6781223)

  • 1. Effects of different monoamine oxidase inhibitors on respiratory activity in rats with chronically impaired central serotonergic function.
    Mueller RA; Lundberg D; Breese G
    Acta Pharmacol Toxicol (Copenh); 1980 Oct; 47(4):285-93. PubMed ID: 6781223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence that respiratory depression by serotonin agonists may be exerted in the central nervous system.
    Mueller RA; Lundberg D; Breese GR
    Pharmacol Biochem Behav; 1980 Aug; 13(2):247-55. PubMed ID: 6968074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An evaluation of the mechanism by which serotonergic activation depresses respiration.
    Lundberg DB; Mueller RA; Breese GR
    J Pharmacol Exp Ther; 1980 Mar; 212(3):397-404. PubMed ID: 6965719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of vagal afferents and carbon dioxide in the respiratory response to thyrotropin-releasing hormone.
    Mueller RA; Towle AC; Breese GR
    Regul Pept; 1985 Mar; 10(2-3):157-66. PubMed ID: 3922012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical and behavioral alterations in developing rats treated with 5,7-dihydroxytryptamine.
    Breese GR; Vogel RA; Mueller RA
    J Pharmacol Exp Ther; 1978 Jun; 205(3):587-95. PubMed ID: 307057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-propargylbenzylamine, a major metabolite of pargyline, is a potent inhibitor of monoamine oxidase type B in rats in vivo: a comparison with deprenyl.
    Karoum F
    Br J Pharmacol; 1987 Feb; 90(2):335-45. PubMed ID: 3103805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Supersensitivity to the respiratory stimulatory effect of TRH in 5,7-dihydroxytryptamine-treated rats.
    Mueller RA; Towle AC; Breese GR
    Brain Res; 1984 Apr; 298(2):370-3. PubMed ID: 6426700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoamine receptor sensitivity changes following chronic administration of MDL 72394, a site-directed inhibitor of monoamine oxidase.
    Palfreyman MG; Mir AK; Kubina M; Middlemiss DN; Richards M; Tricklebank MD; Fozard JR
    Eur J Pharmacol; 1986 Oct; 130(1-2):73-89. PubMed ID: 3780861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of 5,6-dihydroxytryptamine and 5,7-dihydroxytryptamine on the rat central nervous system after intraventricular or intracerebral application and on blood platelets in vitro.
    Da Prada M; Pieri L; Keller HH; Pieri M; Bonetti EP
    Ann N Y Acad Sci; 1978 Jun; 305():595-620. PubMed ID: 152083
    [No Abstract]   [Full Text] [Related]  

  • 10. Serotonergic properties of beta-phenethylamine in rats.
    Sloviter RS; Connor JD; Drust EG
    Neuropharmacology; 1980 Nov; 19(11):1071-4. PubMed ID: 6449675
    [No Abstract]   [Full Text] [Related]  

  • 11. Cardiovascular functions of brain serotonergic neurons in the rabbit as analysed from the acute and chronic effects of 5,6-dihydroxytryptamine.
    Head GA; Korner PI
    J Cardiovasc Pharmacol; 1982; 4(3):398-408. PubMed ID: 6177936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intracortical 5,7-dihydroxytryptamine depletes brain serotonin concentrations without affecting spontaneous activity.
    Black RS; Robinson RG
    Pharmacol Biochem Behav; 1985 Feb; 22(2):327-31. PubMed ID: 3983223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Behavioral and biochemical interactions of 5,7-dihydroxytryptamine with various drugs when administered intracisternally to adult and developing rats.
    Breese GR; Cooper BR
    Brain Res; 1975 Nov; 98(3):517-27. PubMed ID: 1242372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Supersensitivity of 5,7-dihydroxytryptamine-treated rats to the respiratory depressant and antitussive effects of dihydrocodeine.
    Kamei J; Ogawa M; Kasuya Y
    Eur J Pharmacol; 1988 Aug; 153(2-3):305-8. PubMed ID: 3181291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of a new, short-acting and specific inhibitor of type A monoamine oxidase.
    Waldmeier PC; Baumann PA; Delini-Stula A; Bernasconi R; Sigg K; Buech O; Felner AE
    Mod Probl Pharmacopsychiatry; 1983; 19():31-52. PubMed ID: 6191211
    [No Abstract]   [Full Text] [Related]  

  • 16. Alteration of aminophylline-induced respiratory stimulation by perturbation of biogenic amine systems.
    Mueller RA; Lundberg DB; Breese GR
    J Pharmacol Exp Ther; 1981 Sep; 218(3):593-9. PubMed ID: 7264947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modification of serotonergic and noradrenergic neurotransmissions by repeated administration of monoamine oxidase inhibitors: electrophysiological studies in the rat central nervous system.
    Blier P; De Montigny C; Azzaro AJ
    J Pharmacol Exp Ther; 1986 Jun; 237(3):987-94. PubMed ID: 2423685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of monoamine oxidase in monoaminergic neurones in the rat brain by irreversible inhibitors.
    Fagervall I; Ross SB
    Biochem Pharmacol; 1986 Apr; 35(8):1381-7. PubMed ID: 2870717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the optical isomers of the narcotic antagonist analgesic pentazocine on brain and heart biogenic amines.
    Berkowitz BA
    Eur J Pharmacol; 1974 May; 26(2):359-65. PubMed ID: 4152866
    [No Abstract]   [Full Text] [Related]  

  • 20. Chronic treatment with the monoamine oxidase inhibitors clorgyline and pargyline down-regulates non-adrenoceptor [3H]-idazoxan binding sites in the rat brain.
    Olmos G; Gabilondo AM; Miralles A; Escriba PV; García-Sevilla JA
    Br J Pharmacol; 1993 Mar; 108(3):597-603. PubMed ID: 8385528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.